COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Protocol No
ALLIANCE-A051301-CTN1201
Principal Investigator
Timothy Fenske
Phase
III
Summary
To directly compare any good and bad effects of using an oral medication, ibrutinib, along with the AutoHCT versus AutoHCT alone.
Description
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With R/R DLBCL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL